© 2025 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Grace Halsey
Articles
Inhaled Psychedelic GH001 Significantly and Rapidly Reduces Symptoms in Treatment Resistant Depression in Phase 2b Clinical Trial
February 04, 2025
GH001, an inhalable 5-MeO-DMT therapy, led to a -15.5 MADRS score reduction by day 8 in patients with treatment-resistant depression.
Where Will the New Nonopioiod Suzetrigine (Journavx) Fit Best Along the Acute Pain Management Continuum? Phase 3 Investigator Shares Thoughts
February 03, 2025
Suzetrigine (Journavx) PI Todd Bertoch, MD, identifies the sweet spot where he thinks the new NaV1.8 inhibitor will be most effective in post-surgical and other moderate-to-severe acute pain.
Global Migraine Burden Rising Fastest Among Men and Adolescents, New Research Finds
February 03, 2025
The global burden of migraine rose by 58% between 1990 and 2021 to more than 1 billion, a pace projected to continue and most rapidly among men and young people.
Vaccine Distrust, Emboldened During the Pandemic, Runs Deep: An Expert Perspective
February 02, 2025
Robert Hopkins, Jr, MD, says of official communications during the COVID-19 pandemic that not enough was explained to the public about policy shifts, leaving people wondering.
Symbravo (AXS-07) for Treatment of Acute Migraine in Adults: Phase 3 Trial Primer
January 31, 2025
The pivotal INTERCEPT and MOMENTUM phase 3 clinical trials served as foundational evidence for the efficacy of the combination therapy across migraine presentations.
Pain Expert Edward Mariano, MD, MAS, Highlights Journavx and the Newly-Approved Nonopioid's Mechanism of Action
January 31, 2025
Mariano, a well-known researcher in regional anesthesiology and acute pain medicine, talks about the Journavx difference, including the drug's safety profile.
Journavx Approval: Lead Investigator Highlights Pivotal Phase 3 Clinical Trials
January 30, 2025
Todd Bertoch, MD, reviews the significant findings on relief of pain from the 2 pivotal studies and lauds the remarkable safety profile of the novel nonopoid analgesic Journavx.
FDA Approves Journavx, First-in-Class Nonopioid Analgesic for Moderate-to-Severe Acute Pain
January 30, 2025
Journavx is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years.
Axsome Therapeutics: FDA Approves Symbravo for Acute Treatment of Migraine
January 30, 2025
A single oral dose of Symbravo provided rapid migraine pain freedom and return to normal functioning within 2 hours, and sustained efficacy through 24 and 48 hours.
Tezepelumab Misses Primary Endpoint in Phase 2a COURSE Trial of Moderate to Very Severe COPD
January 30, 2025
Although the study missed the primary endpoint, subgroup analyses found variable efficacy based on baseline BECs, suggesting potential benefits in specific subgroups.